Search research articles
Contact Us
Filters
Showing results (1-10 of 265) with videos related to
Page
of 27
Sort By:
Oncology (Williston Park, N.Y.)
|
February 4, 2010
Tamoxifen, endoxifen, and CYP2D6: the rules for evaluating a predictive factor
Matthew P Goetz
Clinical Advances in Hematology & Oncology : H&O
|
May 10, 2018
The development of endoxifen for breast cancer
Matthew P Goetz
Clinical Advances in Hematology & Oncology : H&O
|
October 23, 2010
Update on CYP2D6 and its impact on tamoxifen therapy
Matthew P Goetz
Clinical Advances in Hematology & Oncology : H&O
|
April 20, 2013
Update on CYP2D6 and Tamoxifen
Matthew P Goetz
Expert Review of Anticancer Therapy
|
July 24, 2004
Developments in combination chemotherapy for colorectal cancer
Matthew P Goetz, Axel Grothey
Clinical Colorectal Cancer
|
June 24, 2004
Oxaliplatin plus oral fluoropyrimidines in colorectal cancer
Axel Grothey, Matthew P Goetz
Cancer
|
September 28, 2007
Early discontinuation of tamoxifen: a lesson for oncologists
Matthew P Goetz, James Ingle
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 23, 2016
Window-of-Opportunity Trials in the Preoperative Setting: Insights Into Drug Development for Estrogen Receptor-Positive Breast Cancer
Matthew P Goetz, Vera J Suman
Nature Clinical Practice. Oncology
|
September 13, 2007
Aromatase inhibitors and tamoxifen: where do we go from here?
Matthew P Goetz, Charles L Loprinzi
Annals of Surgical Oncology
|
March 3, 2015
Landscape of neoadjuvant therapy for breast cancer
Tufia C Haddad, Matthew P Goetz
Page
of 27
Search research articles
Search
Showing results (1-10 of 265) with videos related to
Sort By:
Page
of 27
Oncology (Williston Park, N.Y.)
|
February 4, 2010
Tamoxifen, endoxifen, and CYP2D6: the rules for evaluating a predictive factor
Matthew P Goetz
Clinical Advances in Hematology & Oncology : H&O
|
May 10, 2018
The development of endoxifen for breast cancer
Matthew P Goetz
Clinical Advances in Hematology & Oncology : H&O
|
October 23, 2010
Update on CYP2D6 and its impact on tamoxifen therapy
Matthew P Goetz
Clinical Advances in Hematology & Oncology : H&O
|
April 20, 2013
Update on CYP2D6 and Tamoxifen
Matthew P Goetz
Expert Review of Anticancer Therapy
|
July 24, 2004
Developments in combination chemotherapy for colorectal cancer
Matthew P Goetz, Axel Grothey
Clinical Colorectal Cancer
|
June 24, 2004
Oxaliplatin plus oral fluoropyrimidines in colorectal cancer
Axel Grothey, Matthew P Goetz
Cancer
|
September 28, 2007
Early discontinuation of tamoxifen: a lesson for oncologists
Matthew P Goetz, James Ingle
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 23, 2016
Window-of-Opportunity Trials in the Preoperative Setting: Insights Into Drug Development for Estrogen Receptor-Positive Breast Cancer
Matthew P Goetz, Vera J Suman
Nature Clinical Practice. Oncology
|
September 13, 2007
Aromatase inhibitors and tamoxifen: where do we go from here?
Matthew P Goetz, Charles L Loprinzi
Annals of Surgical Oncology
|
March 3, 2015
Landscape of neoadjuvant therapy for breast cancer
Tufia C Haddad, Matthew P Goetz
Page
of 27